Opioid manufacturer admits to illegal activity in the United States but faces no penalties in Canada
Purdue Pharma recently announced that it will stop advertising opioids to doctors in the United States after pleading guilty to misleading marketing more than a decade ago. This is a major, albeit belated, departure from the company’s playbook of marketing opioids aggressively to physicians. A recent U.S. Senate report excoriated Purdue Pharma and other opioid manufacturers for funding patient advocacy groups for years.
We have the same tragic opioid crisis here in Canada relative to the U.S. — 3000 deaths per year in Canada compared to 30,000 in the United States — and trail only the U.S. when it comes to opioid prescribing rates. But unlike our neighbours, Canadian governments have not taken similar actions against Purdue Pharma.
Canadians pay for this inaction.
Although the hundreds of millions in penalties paid in the U.S. are not trivial amounts, they are still a small fraction of Purdue Pharma’s profits from the opioid crisis. And there are now many companies selling the types of products that Purdue flogged at the start of the crisis. Drug manufacturers are sure to do the simple arithmetic: huge profits minus small penalties equals lucrative profits.
The math is even simpler in Canada. There are no government penalties here.
Health Canada regulates drug manufacturers, but it has never sanctioned Purdue Pharma. Not once. The federal Competition Bureau enforces the Competition Act which prohibits false and misleading marketing, but it has shown no interest in the opioid crisis. The Patent Medicine Prices Review Board has also been silent on the issue.
Provincial governments continue to publicly fund high dose opioid products made by Purdue Pharma and other companies. The Ontario government even awarded Purdue Pharma a 4.9 million dollar grant in 2007, the same year the company pleaded guilty in the U.S. And in advance of Ontario’s leading push towards increasing transparency for drug company payments to prescribers, Purdue Pharma ended up disclosingthree million dollars in payments to health providers in Canada during 2016 alone.
The message sent by Canadian governments to Purdue Pharma and other drug makers is clear: we are not prepared to hold you accountable for a crisis you helped manufacture. That message is surely received by other drug manufacturers as well.
To be sure, this is an extreme example of a company that has already plead guilty in another country. If Canadian governments cannot muster the strength to respond in this case with hundreds of deaths each month attributed to opioids, will they ever prosecute self-admitted misbehavior by a pharmaceutical company?
The settlement in the 2017 Canadian class-action lawsuit against Purdue Pharma shows why Canadian governments must act quickly. The people harmed by the opioid crisis decided to accept a small settlement rather than try to take on a behemoth in the courtroom. That makes perfect sense.
Stunningly, Canadian governments left those harmed by the crisis to fend for themselves and agreed to a settlement of just $2 million dollars in total for all of the harms associated with the opioid crisis. Both Purdue Pharma’s revenues and the toll of the opioid crisis in Canada are measured in the billions.
We believe a criminal investigation into the marketing of opioid products in Canada should be opened. This has already been openly recommended by the Minister of Health for Ontario.
Purdue Pharma may decide not to risk an open airing of the evidence and instead plead guilty as they already did in the U.S. But even an unsuccessful prosecution will remind Purdue Pharma and other opioid manufacturers that there are laws in this country too and provide at least a semblance of justice.
In the meantime, both the marketing to physicians that Purdue Pharma voluntarily stopped in the U.S. and the funding of advocacy groups must also be halted in Canada. Too many lives have already been lost. As Canadian communities continue to feel the brunt of the opioid crisis, it is well past time that Canadian governments finally stand up to Purdue Pharma.
Nav Persaud is a family physician and an assistant professor at the University of Toronto and an expert advisor with EvidenceNetwork.ca.
Andrew S. Boozary is a resident physician at the University of Toronto and visiting scientist at the Harvard T.H. Chan School of Public Health.
This work is licensed under a Creative Commons Attribution 4.0 International License.